<DOC>
	<DOC>NCT01975324</DOC>
	<brief_summary>Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.</brief_summary>
	<brief_title>A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)</brief_title>
	<detailed_description>The aim of this study is to determine whether dalfampridine can improve visual function in patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment. The objective of this double masked crossover study is to determine whether visual function can be improved in numerous parameters. This includes high contrast visual acuity, low contrast visual acuity, visual field, visual quality of life (VFQ-39), electrophysiology, multi focal electro retinography (mERG), visual evoked potential (VEP), and structure, spectral domain optical coherence tomography (OCT). Based on the promising results of the use of dalfampridine in Multiple Sclerosis (MS) and in stroke, we hypothesize that the patients with chronic stable deficits after nonarteritic ischemic optic neuropathy (NAION) will have improved visual function with the administration of dalfampridine.</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Neuropathy, Ischemic</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>NAION 6 months prior to enrollment visual acuity of 20/40 or worse Current use of Dalfampridine (Ampyra) Pregnancy History of seizures Renal Failure Not able to perform testing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Ampyra</keyword>
	<keyword>NAION</keyword>
	<keyword>Dalfampridine</keyword>
</DOC>